Latest News and Updates

* (R) = Regulatory press releases

Nov 10, 2023

(R) Cantargia publishes interim report for third quarter 2023

Nov 3, 2023

(R) Nomination Committee appointed ahead of 2024 Annual General Meeting

Oct 30, 2023

(R) Cantargia has completed a directed share issue of approximately SEK 59 million

Oct 26, 2023

Invitation to presentation of Cantargia’s report for the third quarter of 2023 on November 10 at 3.00 p.m. CET

Oct 21, 2023

(R) Cantargia: ESMO 2023 presentation of nadunolimab phase I clinical interim data in triple-negative breast cancer shows promising efficacy and safety

Oct 16, 2023

Cantargia to present clinical phase Ib data on nadunolimab in triple-negative breast cancer at ESMO Congress 2023

Oct 4, 2023

(R) Cantargia: Third party appeals recent EPO decision to maintain granted Cantargia patent

Sep 29, 2023

Cantargia publishes AACR Special Conference poster on new nadunolimab clinical and biomarker data in pancreatic cancer

Sep 27, 2023

(R) Cantargia presents new clinical data further supporting nadunolimab’s antitumor activity and a key role of its target IL1RAP in pancreatic cancer

Sep 20, 2023

(R) Cantargia: New preclinical data on nadunolimab potential to enhance anti-tumor effect of immunotherapy presented at CRI-ENCI-AACR

<< Newer press releases Older press releases >>

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye

Press releases

(R) Cantargia publishes interim report for third quarter 2023

(R) Nomination Committee appointed ahead of 2024 Annual General Meeting

(R) Cantargia has completed a directed share issue of approximately SEK 59 million

Invitation to presentation of Cantargia’s report for the third quarter of 2023 on November 10 at 3.00 p.m. CET

(R) Cantargia: ESMO 2023 presentation of nadunolimab phase I clinical interim data in triple-negative breast cancer shows promising efficacy and safety

Cantargia to present clinical phase Ib data on nadunolimab in triple-negative breast cancer at ESMO Congress 2023

(R) Cantargia: Third party appeals recent EPO decision to maintain granted Cantargia patent

Cantargia publishes AACR Special Conference poster on new nadunolimab clinical and biomarker data in pancreatic cancer

(R) Cantargia presents new clinical data further supporting nadunolimab’s antitumor activity and a key role of its target IL1RAP in pancreatic cancer

(R) Cantargia: New preclinical data on nadunolimab potential to enhance anti-tumor effect of immunotherapy presented at CRI-ENCI-AACR

In media

Interview with CEO Hilde H. Steineger - 2025-10-24

Interview with CEO Hilde H. Steineger - 2025-10-07

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye interviews Interim CEO Damian Marron - 2025-02-07